Crohn's disease in women

International Journal of Women's Health

Volumn 5, Issue 1, 2012, Pages 681-688

  Plavšic, Ivana ^a   Štimac, Tea ^b   Hauser, Goran ^b  

^a Public Health Center   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

Adverse pregnancy outcome; Crohn's disease; Gynecological complications; Immunosuppressive therapy

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE;

COLON SURGERY; CONGENITAL MALFORMATION; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; GYNECOLOGY; HIGH RISK PATIENT; HUMAN; LOW BIRTH WEIGHT; MENSTRUAL CYCLE; MORBIDITY; OBSTETRICS; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; REMISSION; REVIEW;

EID: 84886942754     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S38083     Document Type: Review

References (80)

1. Molodecky NA, Soon IS, Rabi DM, etal. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54. e42.
2. Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. 2013 May 20. [Epub ahead of print].
3. Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17:2702-2707.
4. Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis. 2001;7(4):306-313.
5. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and Prevalence of Inflammatory Bowel Disease in a Northern California Managed Care Organization 1996-2002. Am J Gastroenterol. 2008;103(8):1998-2006.
6. Beaulieu DB, Kane S. Inflammatory bowel disease in pregnancy. World J Gastroenterol. 2011;17(22): 2696-2701.
7. Mahedavan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 2006;55(8):1198-1206.
8. Hudson M, Flett G, Sinclair TS, Brunt PW, Templeton A, Mowat NA. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997;58(2):229-237.
9. Selinger SP, Leong RW, Lal S. Pregnancy related issues in inflammatory bowel disease: Evidence base and patients' perspective. World J Gastroenterol. 2012;18(21):2600-2608.
10. Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis. 2008;14(12):1736-1750.
11. Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(5):591-599.
12. Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15(5):720-725.
13. Selinger CP, Eaden J, Selby W, etal. Patients' knowledge of pregnancy-related issues in inflammatory bowel disease and validation of a novel assessment tool ('CCPKnow').(Abstract) Aliment Pharmacol Ther. 2012;36(1):57-63.
14. Selinger CP, Eaden J, Selby W, etal. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. (Abstract) J Crohns Colitis. 2013;7(6):e206-13.
15. Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic Drug Use in Women with Crohn's Disease and Birth Outcomes: A Danish nationwide cohort study. Am J Gastroenterol. 2007;102:1406-1413.
16. Cornish J, Tan E, Teare J, etal. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56(6):830-837.
17. Van Assche G, Dignass A, Reinisch W, etal; European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis. 2010;4(1):63-101.
18. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology. 1990;99(4):987-994.
19. Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad Med J. 2002;78(915):23-26.
20. Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am J Gastroenterol. 2002;97(3):641-648.
21. Bortoli A, Saibeni S, Tatarella M, etal; Study Group for Inflammatory Bowel Diseases GSMII. Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J Gastroenterol Hepatol. 2007;22(4):542-549.
22. Sides C, Trinidad MC, Heitlinger L, Anasti J. Chron disease and the gynecologic patient. Obstet Gynecol Surv. 2013;68(1):51-61.
23. Bortoli A, Pedersen, N, Duricova D, etal; for the European Crohn-Colitis Organisation (ECCO) Study Group of Epidemiologic Committee (EpiCom). Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther. 2011;34(7):724-734.
24. Fonager K, Sørensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93(12):2426-2430.
25. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103(5):1203-1209.
26. Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease-a population-based cohort study. Am J Obstet Gynecol. 1997;177(4):942-946.
27. Nørgård B, Fonager K, Sørensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol. 2000;95(11):3165-3170.
28. Nørgård B, Puho E, Pedersen L, Czeizel AE, Sørensen HT. Risk of congenital abnormalities in children born to women with ulcerative colitis: a population-based, case-control study. Am J Gastroenterol. 2003;98(9):2006-2010.
29. Ilnyckyj A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am J Gastroenterol. 1999;94(11):3274-3278.
30. Smink M, Lotgering FK, Albers L, de Jong DJ. Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands. BMC Gastroenterol. 2011;11:6.
31. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn's disease. Am J Gastroenterol. 1995;90(11):1918-1922.
32. Kwan LY, Mahedavan U. Inflammatory bowel disease and pregnancy: an update. Expert Rev Clin Immunol. 2010;6(4):643-657.
33. Nielsen OH, Andreasson B, Bondesen S, Jacobsen O, Jarnum S. Pregnancy in Crohn's disease. Scand J Gastroenterol. 1984;19(6):724-732.
34. Agret F, Cosnes J, Hassani Z, etal. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol Ther. 2005;21(5):509-513.
35. Riis L, Vind I, Politi P, etal. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2006;101(7):1539-1545.
36. Castiglione F, Pignata S, Morace F, etal. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital J Gastroenterol. 1996; 28(4),199-204.
37. Nwokolo CU, Tan WC, Andrews HA, Allan RN. Surgical resections in parous patients with distal ileal and colonic Crohn's disease. Gut. 1994;35(2):220-223.
38. Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol. 2004;99(8):1523-1526.
39. Craxi A, Pagliarello F. Possible embryotoxicity of sulfasalazine. Arch Intern Med. 1980;140(12):1674.
40. Hoo JJ, Hadro TA, Von Behren P. Possible teratogenicity of sulfasalazine. N Engl J Med. 1988;318(17):1128.
41. Newman NM, Correy JF. Possible teratogenicity of sulphasalazine. Med J Aust. 1983;1(11):528-529.
42. Nørgård B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol. 2007;102(9):1947-1954.
43. Marteau P, Tennenbaum R, Elefant E, Lémann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther. 1998;12(11):1101-1108.
44. Diav-Citrin O, Park YH, Veerasuntharam G etal. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998;114(1):23-28.
45. Nørgård B, Fonager K, Pedersen L, Jacobsen BA, Sørensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003;52(2):243-247.
46. Park-Wyllie L, Mazzotta P, Pastuszak A etal. Birth defects after maternal exposure to corticosteroids:prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385-392.
47. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004;18(1):93-101.
48. Administration FDA. Regulations 1980; 44: 37434-37467. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016324s034 s035 lbl.pdf. Accesed May 6, 2013.
49. Nørgård B, Pedersen L, Fonager K, Rasmussen SN, Sørensen HT. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther. 2003;17(6):827-834.
50. Casanova MJ, Chaparro M, Domènech E, etal. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. (Abstract) Am J Gastroenterol. 2013;108(3):433-440.
51. Coelho J, Beaugerie L, Colombel JF, etal; CESAME Pregnancy Study Group (France). Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60(2):198-203.
52. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124(1):9-17.
53. Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion. 2000;62:249-254.
54. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol. 2013;19(17):2591-2602.
55. Mahadevan U, Wolf DC, Dubinsky M, etal. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-292.
56. Mahadevan U, Kane S, Sandborn WJ, etal. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21(6):733-738.
57. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99(12):2385-2392.
58. Gisbert JP, Chaparro M. Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease. Am J Gastroenterol. 2013 Jun 11. [Epub ahead of print]
59. Habal FM, Ravindran NC. Management of inflammatory bowel disease in the pregnant patient. World J Gastroenterol. 2008;14(9):1326-1332.
60. Palamaras I, El-Jabbour J, Pietropaolo N etal. Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol. 2008; 22(9):1033-1043.
61. Andreani SM, Ratnasingham K, Dang HH, Gravante G, Giordano P. Crohn's disease of the vulva. Int J Surg. 2010;8(1):2-5.
62. Leu S, Sun PK, Collyer J, etal. Clinical spectrum of vulva metastatic Crohn's disease. Dig Dis Sci. 2009;54(7):1565-1571.
63. Safar B, Sands D. Perianal Crohn's Disease. Clin Colon Rectal Surg. 2007;20(4):282-293.
64. Hellers G, Bergstrand O, Ewerth S, Holmström B. Occurrence and outcome after primary treatment of anal fistulae in Cohn's disease. Gut. 1980;21(6):525-527.
65. Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6(2):92-106.
66. Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn's disease. Int J Colorectal Dis. 1986;1(2):104-107.
67. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998;93(10):1867-1872.
68. Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn's disease? A population based study. Clin Gastroenterol Hepatol. 2006;4(9):1130-1134.
69. Ruffolo C, Citton M, Scarpa M, etal. Perianal Crohn's disease: Is there something new?. World J Gastroenterol. 2011;17(15):1939-1946.
70. Deveaux PG, Kimberling J, Galandiuk S. Crohn's disease: presentation and severity compared between black patients and white patients. Dis Colon Rectum. 2005;48(7):1404-1409.
71. Kane S. Urogenital complications of Crohn's disease. Am J Gastroenterol. 2006;101(12 Suppl):S640-3.
72. Chu M, Crist H, Zaino RJ. Adenocarcinoma arising in a rectovaginal fistula in Chron disease. Int J Gynecol Pathol. 2010;29(5):497-500.
73. Lim SM, Nam CM, Kim YN, etal. The effect of the menstrual cycle on inflammatory bowel disease: a prospective study. Gut Liver. 2013;7(1):51-57.
74. Borman RA, Tilford NS, Harmer DW, etal. 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002;135(5):1144-1151.
75. Houghton LA, Brown H, Atkinson W, etal. 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status. Aliment Pharmacol Ther. 2009;30(9):919-929.
76. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C, Lu ZN. Ovarian steroids and serotonin neural function. Mol Neurobiol. 1998;18(2):87-123.
77. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med. 2009;6 Suppl 2:152-167.
78. Okoro NI, Kane SV. Gender-related issues in the female inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol. 2009;3(2):145-154.
79. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology. 1995;109(1):285-301.
80. Weber AM, Ziegler C, Belinson JL, Mitchinson AR, Widrich T, Fazio V. Gynecologic history of women with inflammatory bowel disease. Obstet Gynecol. 1995;86(5):843-847.